Print Page Print Page | E-mail Page E-mail Page

News Release

Printer Friendly Version View printer-friendly version
<< Back
Australian Scientist Wins Researchers in Business Project Funding
Mannatech and the University of South Australia will benefit from Dr. Talitha Best's Scientific Expertise

COPPELL, Texas, Sep 20, 2011 (BUSINESS WIRE) --

Mannatech, Incorporated(NASDAQ: MTEX), the leading innovator and provider of nutritional supplements and skin care products based on Real Food Technology(R) solutions, announced today that the Australian government has granted Dr. Talitha Best a 12-month Researchers in Business (RiB) grant to help develop research on Mannatech's glyconutritional products.

The $10 million RiB program is part of Enterprise Connect, an initiative within the Australian government's Department of Innovation, Industry, Science and Research. The program is designed to accelerate industry innovation and competitiveness by connecting university and public agency researchers with businesses that wish to develop new ideas with commercial potential. RiB initiatives are destined to play an important role in enhancing the transfer of university intellectual capital into practical business applications and to stimulate the dissemination of industry knowledge back into the research community. Exciting innovation is expected to flow from breaking down the cultural divide between academia and business.

"Mannatech is pleased to be collaborating with the government of Australia, the University of South Australia (UniSA) and Dr. Talitha Best on this project," said Dr. Robert Sinnott, co-CEO and chief science officer of Mannatech. "Australia has a wonderful business climate, and by virtue of its geographical location, it is a key interface between the Western world and Asia. Australia is a perfect place to develop innovation that will carry companies forward for years to come."

For more than six years, Dr. Best, a post-doctoral research fellow at the Nutritional Physiology Research Centre, UniSA, and the Brain Sciences Institute, Swinburne University of Technology, has been investigating the impact of dietary saccharides on human brain function. She has presented her findings at numerous scientific conferences and has shown, in two randomized, double-blind, placebo-controlled human clinical trials, that intake of Mannatech's saccharide supplement, Ambrotose(R) complex, can provide both immediate and long-term improvements in memory, cognition and well-being (1)+,(2)+*.

"With Australia's reputation as an important contributor to groundbreaking clinical trial glyconutrition research, this grant is both apposite and timely," said George Howden, general manager, Mannatech Australia. "The research and development derived from this project will serve as a catalyst for uncovering new discoveries regarding the impact of glyconutrients on health, thus driving the wellness industry to new heights."

Individuals interested in Mannatech's products or exploring its business opportunity are encouraged to learn more at Mannatech.com.

About Mannatech

Mannatech, Incorporated, develops high-quality health, weight and fitness, and skin care products that are based on the solid foundation of nutritional science and development standards. Mannatech is dedicated to its platform of Social Entrepreneurship based on the foundation of promoting, aiding and optimizing nutrition where it is needed most around the world. Mannatech's proprietary products are available through independent sales Associates around the globe including the United States, Canada, South Africa, Australia, New Zealand, Austria, Denmark, Germany, Norway, Sweden, the Netherlands, the United Kingdom, Japan, Taiwan, Singapore, Estonia, Finland, the Republic of Ireland, Czech Republic, the Republic of Korea and Mexico. For more information, visit Mannatech.com.

Please note: This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as "intend" or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties and other factors. Some of these factors include, among others, Mannatech's inability to attract and retain Associates and Members, increases in competition, litigation, regulatory changes and its planned growth into new international markets. Although Mannatech believes that the expectations, statements and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

1. Best T, Kemps E, Bryan J. Saccharide effects on cognition and well-being in middle-aged adults: A randomized controlled trial. Dev Neuropsych 2010;35:66-80.

2. Best T, Howe P, Bryan J, Buckley J, Scholey A. Plant polysaccharides, memory and cognition in middle-aged adults. Presented at the 38th Australasian Experimental Psychology Conference in Auckland, New Zealand, April 28-30, 2011.

+ Mannatech provided the Ambrotose supplement and placebo used in this study.

+Mannatech provided partial funding and provided the Ambrotose supplement and placebo used in this study.

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.

SOURCE: Mannatech, Incorporated

for Mannatech, Incorporated
Shawn Paul Wood, 972-499-6614
Shawn.Wood@hck2.com